Life Sciences Venture Funding Drops

Life Sciences Venture Funding Drops

October 5, 2012

In today’s economy, capital is much more difficult to raise, and the various sources of investment, from private angels to larger VC firms, are understandably much more cautious and conservative about where they place their money. “The economic recession made its impact on life sciences investments, as there have been negative returns on investments for the last 12 years.

LS9 Scales Up in Chemical Business As Biofuels Industry Re-Tools

LS9 Scales Up in Chemical Business As Biofuels Industry Re-Tools

October 4, 2012

The South San Francisco company LS9 recently produced five tons of industrial chemicals from plant sugars at a Florida demonstration facility, a step toward proving that its genetically engineered microbes can manufacture carbon compounds and fuels at a commercial scale.

T2 Biosystems Named a "Fierce 15" Medical Device and Diagnostic Company of 2012

T2 Biosystems Named a "Fierce 15" Medical Device and Diagnostic Company of 2012

October 2, 2012

LEXINGTON, Mass., Oct 02, 2012 (BUSINESS WIRE) -- T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced that it has been named to the FierceMedicalDevices "Fierce 15" list, designating it as one of the leading medical device and diagnostic companies of 2012.

Shire scoops up Pervasis Therapeutics

Shire scoops up Pervasis Therapeutics

April 12, 2012

By Galen Moore, Boston Business Journal

The Wall Street Journal Names Acceleron to "The Next Big Thing" List of Top 50 Start-Ups in the United States

The Wall Street Journal Names Acceleron to "The Next Big Thing" List of Top 50 Start-Ups in the United States

September 27, 2012

Acceleron one of only two biopharmaceutical companies to make the list

Flagship Ventures CEO keeps Merck aboard to inform biotech bets

Flagship Ventures CEO keeps Merck aboard to inform biotech bets

September 25, 2012

Largely gone are the days when venture capitalists could hatch a biotech and take it public without much regard for the needs of Big Pharma. Public investors seldom buy into new biotech companies, and drugmakers have increasingly become early partners with VC firms and their young ventures. In the process, pharma has gained significant clout in the biotech VC game.

The Energy Of The Future Is Here: AeroShot Energy, New "Air-Based" Energy Product Launches Nationwide

The Energy Of The Future Is Here: AeroShot Energy, New "Air-Based" Energy Product Launches Nationwide

September 20, 2012

AeroShot Energy, a revolutionary air-based energy product invented by Harvard professor David Edwards, will launch across the United States on October 1st.

Black Duck Software Named to Software Magazine's 30th Annual Software 500

Black Duck Software Named to Software Magazine's 30th Annual Software 500

September 20, 2012

Software Magazine Ranks Black Duck as one of the World's Largest and Fastest Growing Software Companies

BURLINGTON, Mass., Sept. 20, 2012 /PRNewswire via COMTEX/ -- Black Duck Software today announced its inclusion in Software Magazine's Software 500 ranking of the world's largest software and service providers, now in its 30th year.

BIND Biosciences Appoints Industry Veteran Daniel Lynch as Chairman of the Board of Directors

BIND Biosciences Appoints Industry Veteran Daniel Lynch as Chairman of the Board of Directors

September 20, 2012

CAMBRIDGE, Mass., Sep 20, 2012 (BUSINESS WIRE) -- BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins(TM), today announced the appointment of Daniel S. Lynch as Chairman of the company's board of directors.

Joule Partners with Audi to Accelerate Development and Commercialization of Sustainable, Carbon-Neutral Fuels

Joule Partners with Audi to Accelerate Development and Commercialization of Sustainable, Carbon-Neutral Fuels

September 17, 2012

BEDFORD, Mass.--(BUSINESS WIRE)--